Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

With a presence in over 500 clinics around the world, Xstrahl have drawn upon their vast clinical expertise to develop a revolutionary system that has been specifically designed for the treatment superficial skin cancers and skin conditions. [More]
Soldiers deployed to sunny climates face increased risk of skin cancer

Soldiers deployed to sunny climates face increased risk of skin cancer

Soldiers deployed to tropical and sunny climates are coming home with increased risk factors for a threat far from the battlefield: skin cancer. [More]
Multi-purpose swabs available from Qosina

Multi-purpose swabs available from Qosina

Qosina offers a wide selection of high quality and economical single-use swabs, in addition to its extensive line of single-use components. These products can be used for countless applications in the medical, biological, chemical, pharmaceutical, optical, electronic, industrial, cosmetic, and dermatological industries. Available in a variety of materials, shapes, and sizes, these swabs are ideal for general cleaning, applying or removing product, sample retrieval, and other precision applications. [More]
University of Michigan Health System becomes one of best places for young doctors to train

University of Michigan Health System becomes one of best places for young doctors to train

Doctors nationwide rate the University of Michigan Health System as one of the best places for young doctors to train in their chosen field, across 20 medical specialties, according to a new ranking released today. [More]
Researchers discover new details of how autoantibodies destroy healthy cells in skin

Researchers discover new details of how autoantibodies destroy healthy cells in skin

University at Buffalo researchers and colleagues studying a rare, blistering disease have discovered new details of how autoantibodies destroy healthy cells in skin. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Morning hypertension unmasked as risk factor for cardiovascular events

Morning hypertension unmasked as risk factor for cardiovascular events

Patients on antihypertensive medication who have high blood pressure in the morning, as measured with home monitoring kits, are at increased risk of cardiovascular events, even if their clinic measurement is acceptable, researchers have found. [More]
Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine. [More]
Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests. [More]

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased.1 The data also confirm two treatment cycles of Picato® are well tolerated by patients.2 [More]
Findings may help develop biomarkers to identify HIV patients at risk of dementia

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Since the introduction of the combination anti-retroviral therapy (cART) in the mid-90s, the life expectancy of HIV patients has significantly improved. As a result, long-term complications are becoming more relevant: almost every second HIV patient is affected by neurocognitive disorders, which can lead to dementia. [More]

BioPhotas launches Celluma ELITE for sale to Aesthetic Physician Market

BioPhotas, Inc. today announced the launch of the Celluma ELITE for sale to the Aesthetic Physician Market. The LED therapy device is stand-mounted and able to be precisely positioned over an area of treatment via an articulating arm and a patented shape-taking light panel. [More]
Blood pressure self-management suitable for high-risk patients

Blood pressure self-management suitable for high-risk patients

Patients with hypertension and high cardiovascular risk can successfully monitor and titrate their own antihypertensive medication, shows research published in JAMA. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
InnoPharma receives FDA approval for generic DACOGEN

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN. [More]
Risk-based treatment approach should be considered for patients with hypertension

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis. [More]
Lifestyle intervention shows kidney benefits in diabetic patients

Lifestyle intervention shows kidney benefits in diabetic patients

A lifestyle intervention focused on weight loss and increasing physical activity should be considered as additional treatment to prevent advanced kidney disease in overweight or obese people with Type 2 diabetes, say researchers. [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]

eRelevance completes integration with Nextech for Plastic Surgery and Dermatology practices

eRelevance Corporation (www.erelevancecorp.com), a progressive Health IT services company, announced today that it has completed integration with Nextech, a popular Electronic Medical Records (EMR) solution for Plastic Surgery and Dermatology practices. [More]
Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. [More]